Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TVP-1012 long-term extension in early Parkinson's disease
NCT02337751Phase 3Completed
- Sponsor
- Takeda
- Start
- Jul 2015
- Primary completion
- Mar 2017
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of rasagiline in Parkinson's disease (PD), sponsored by Takeda. Started Jul 2015; status: completed.
02
Drugs
rasagiline
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02337751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02337751.